35 results on '"Schulze, Andrea"'
Search Results
2. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
- Author
-
Abraham, Prema, Aderman, Christopher, Akiyama, Kunihiko, Alfaro, Daniel V., Ali, Fareed A., Amini, Payam, Anzalotta, Andres Emanuelli, Bátor, György, Batlle, Ivan, Berger, Adam, Bhandari, Ramanath, Bridges, William, Brinkmann, Christian, Brown, Jamin, Burgess, Stuart, Calzada, Jorge, Capone Jr., Antonio, Cervena, Dana, Charles, Steven, Chaudhry, Nauman, Chow, David, Clark, W. Lloyd, Conrad III, Paul, Cunningham, Matthew, Dadgostar, Hajir, Dessouki, Amr, Deupree, Dana, Devine, Christopher, Eichenbaum, David, Ernest, Jan, Feltgen, Nicolas, Fenberg, Moss, Ferrone, Philip, Frenkel, Ronald, Friedman, Scott, Gasperini, Julie, Gerstenblith, Adam, Ghorayeb, Ghassan, Giunta, Michel, Goff, Mitchell, Golas, Liliya, Googe Jr., Joseph M., Goren Fein, Jordana, Hagedorn, Curtis, Hagiwara, Akira, Hahn, Paul, Hairston, Richard, Handza, Jason, Hau, Vivienne, Hayashi, Ken, Heier, Jeffrey, Hershberger, Vrinda, Higgins, Patrick, Hirano, Yoshio, Honda, Shigeru, Ikegami, Yasuko, Ishida, Yuichiro, Ishikawa, Isao, Ishii, Kiyoshi, Jablon, Eric P., Jain, Atul, Kaji, Yuichi, Kapoor, Kapil, Kerényi, Ágnes, Kimura, Kazuhiro, Kishino, Genichiro, Kiss, Katalin, Kitaoka, Takashi, Klancnik, James M., Kobayashi, Namie, Kogo, Jiro, Korda, Vladimir, Kruger, Erik, Kusuhara, Sentaro, Lara, Wilfredo, Laud, Ketan, Lee, Seong, Luu, James, Marcus, Dennis, Mein, Calvin, Meleth, Annal, Milibák, Tibor, Mitamura, Yoshinori, Murata, Toshinori, Noge, Sumiyo, Onoe, Hajime, Osher, James, Papp, András, Parschauer, Justin, Patel, Sugat, Patel, Sunil, Pezda, Matthew, Pirouz, Ashkan, Prasad, Pradeep, Punjabi, Omar, Rao, Llewelyn, Roe, Richard, Schadlu, Ramin, Schneider, Eric, Shah, Ankur, Shah, Milan, Shah, Sandeep, Shah, Sumit, Sharma, Ashish, Sheth, Veeral, Shimura, Masahiko, Singerman, Lawrence, Spital, Georg, Stoltz, Robert, Suan, Eric, Suzuma, Kiyoshi, Takahashi, Hidenori, Takamura, Yoshihiro, Takeuchi, Masaru, Tan, Jeffrey, Thomas, Benjamin, Tóth,-Molnár, Edit, Ueda, Tetsuo, Ushida, Hiroaki, Vajas, Attila, Varma, Deepali, Varsányi, Balázs, Veith, Miroslav, Weber, Pamela, Wee, Raymond, Williams, Geoff, Yamada, Haruhiko, Yonekawa, Yoshihiro, Yoshida, Shigeo, Brown, David M, Boyer, David S, Do, Diana V, Wykoff, Charles C, Sakamoto, Taiji, Win, Peter, Joshi, Sunir, Salehi-Had, Hani, Seres, András, Berliner, Alyson J, Leal, Sergio, Vitti, Robert, Chu, Karen W, Reed, Kimberly, Rao, Rohini, Cheng, Yenchieh, Sun, Wei, Voronca, Delia, Bhore, Rafia, Schmidt-Ott, Ursula, Schmelter, Thomas, Schulze, Andrea, Zhang, Xin, Hirshberg, Boaz, Yancopoulos, George D, and Sivaprasad, Sobha
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals
- Author
-
Struck, Julian P., Schnoor, Maike, Schulze, Andrea, Hupe, Marie C., Ozimek, Tomasz, Oppolzer, Immanuel A., Schnabel, Marco J., Burger, Maximilian, Darr, Christopher, Gruenwald, Viktor, Hadaschik, Boris, Weinke, Maximilian, Kuebler, Hubert, Klockenbusch, Jonas C., Grabbert, Markus T., Gratzke, Christian, Kramer, Mario W., Katalinic, Alexander, and Merseburger, Axel S.
- Published
- 2022
- Full Text
- View/download PDF
4. Two-colour single-molecule photoinduced electron transfer fluorescence imaging microscopy of chaperone dynamics
- Author
-
Schubert, Jonathan, Schulze, Andrea, Prodromou, Chrisostomos, and Neuweiler, Hannes
- Published
- 2021
- Full Text
- View/download PDF
5. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial
- Author
-
Jensen, Jeffrey T., Lukkari-Lax, Eeva, Schulze, Andrea, Wahdan, Yesmean, Serrani, Marco, and Kroll, Robin
- Published
- 2022
- Full Text
- View/download PDF
6. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
- Author
-
Brown, David M, Boyer, David S, Do, Diana V, Wykoff, Charles C, Sakamoto, Taiji, Win, Peter, Joshi, Sunir, Salehi-Had, Hani, Seres, András, Berliner, Alyson J, Leal, Sergio, Vitti, Robert, Chu, Karen W, Reed, Kimberly, Rao, Rohini, Cheng, Yenchieh, Sun, Wei, Voronca, Delia, Bhore, Rafia, Schmidt-Ott, Ursula, Schmelter, Thomas, Schulze, Andrea, Zhang, Xin, Hirshberg, Boaz, Yancopoulos, George D, Sivaprasad, Sobha, Abraham, Prema, Aderman, Christopher, Akiyama, Kunihiko, Alfaro, Daniel V., Ali, Fareed A., Amini, Payam, Anzalotta, Andres Emanuelli, Bátor, György, Batlle, Ivan, Berger, Adam, Bhandari, Ramanath, Bridges, William, Brinkmann, Christian, Brown, Jamin, Burgess, Stuart, Calzada, Jorge, Capone Jr., Antonio, Cervena, Dana, Charles, Steven, Chaudhry, Nauman, Chow, David, Clark, W. Lloyd, Conrad III, Paul, Cunningham, Matthew, Dadgostar, Hajir, Dessouki, Amr, Deupree, Dana, Devine, Christopher, Eichenbaum, David, Ernest, Jan, Feltgen, Nicolas, Fenberg, Moss, Ferrone, Philip, Frenkel, Ronald, Friedman, Scott, Gasperini, Julie, Gerstenblith, Adam, Ghorayeb, Ghassan, Giunta, Michel, Goff, Mitchell, Golas, Liliya, Googe Jr., Joseph M., Goren Fein, Jordana, Hagedorn, Curtis, Hagiwara, Akira, Hahn, Paul, Hairston, Richard, Handza, Jason, Hau, Vivienne, Hayashi, Ken, Heier, Jeffrey, Hershberger, Vrinda, Higgins, Patrick, Hirano, Yoshio, Honda, Shigeru, Ikegami, Yasuko, Ishida, Yuichiro, Ishikawa, Isao, Ishii, Kiyoshi, Jablon, Eric P., Jain, Atul, Kaji, Yuichi, Kapoor, Kapil, Kerényi, Ágnes, Kimura, Kazuhiro, Kishino, Genichiro, Kiss, Katalin, Kitaoka, Takashi, Klancnik, James M., Kobayashi, Namie, Kogo, Jiro, Korda, Vladimir, Kruger, Erik, Kusuhara, Sentaro, Lara, Wilfredo, Laud, Ketan, Lee, Seong, Luu, James, Marcus, Dennis, Mein, Calvin, Meleth, Annal, Milibák, Tibor, Mitamura, Yoshinori, Murata, Toshinori, Noge, Sumiyo, Onoe, Hajime, Osher, James, Papp, András, Parschauer, Justin, Patel, Sugat, Patel, Sunil, Pezda, Matthew, Pirouz, Ashkan, Prasad, Pradeep, Punjabi, Omar, Rao, Llewelyn, Roe, Richard, Schadlu, Ramin, Schneider, Eric, Shah, Ankur, Shah, Milan, Shah, Sandeep, Shah, Sumit, Sharma, Ashish, Sheth, Veeral, Shimura, Masahiko, Singerman, Lawrence, Spital, Georg, Stoltz, Robert, Suan, Eric, Suzuma, Kiyoshi, Takahashi, Hidenori, Takamura, Yoshihiro, Takeuchi, Masaru, Tan, Jeffrey, Thomas, Benjamin, Tóth, Edit, -Molnár, Ueda, Tetsuo, Ushida, Hiroaki, Vajas, Attila, Varma, Deepali, Varsányi, Balázs, Veith, Miroslav, Weber, Pamela, Wee, Raymond, Williams, Geoff, Yamada, Haruhiko, Yonekawa, Yoshihiro, and Yoshida, Shigeo
- Abstract
A high-dose formulation of intravitreal aflibercept (8 mg) could improve treatment outcomes in diabetic macular oedema (DMO) by requiring fewer injections than the standard comparator, aflibercept 2 mg. We report efficacy and safety results of aflibercept 8 mg versus 2 mg in patients with DMO.
- Published
- 2024
- Full Text
- View/download PDF
7. Contraceptive Efficacy and Safety of 52 mg LNG-IUS for up to Eight Years: Year 6 Data From the Mirena Extension Trial [OP04-1D]
- Author
-
Jensen, Jeffrey T., Kroll, Robin, Lynen, Richard F., Schulze, Andrea, and Lukkari-Lax, Eeva
- Published
- 2020
- Full Text
- View/download PDF
8. Cooperation of local motions in the Hsp90 molecular chaperone ATPase mechanism
- Author
-
Schulze, Andrea, Beliu, Gerti, Helmerich, Dominic A, Schubert, Jonathan, Pearl, Laurence H, Prodromou, Chrisostomos, and Neuweiler, Hannes
- Published
- 2016
- Full Text
- View/download PDF
9. Contraceptive Efficacy and Safety of 52 mg Levonorgestrel-Releasing Intrauterine Systems During Years 6–8 of Use: Data From the Mirena Extension Trial [A13]
- Author
-
Jensen, Jeffrey T., primary, Lukkari-Lax, Eeva, additional, Schulze, Andrea, additional, Baisden, Kristie W., additional, Serrani, Marco, additional, and Kroll, Robin, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Freizeitmobilität im Alltag
- Author
-
Karg, Georg, Zängler, Thomas, Schulze, Andrea, and Institut für Mobilitätsforschung
- Published
- 2000
- Full Text
- View/download PDF
11. Impact of COVID-19 crisis on medical care of patients with metastasized uro-oncologic disease under systemic cancer therapy: a multicenter study in German university hospitals
- Author
-
Struck, Julian P., primary, Schnoor, Maike, additional, Schulze, Andrea, additional, Hupe, Marie C., additional, Ozimek, Tomasz, additional, Oppolzer, Immanuel A., additional, Schnabel, Marco J., additional, Burger, Maximilian, additional, Darr, Christopher, additional, Gruenwald, Viktor, additional, Hadaschik, Boris, additional, Weinke, Maximilian, additional, Kuebler, Hubert, additional, Klockenbusch, Jonas C., additional, Grabbert, Markus T., additional, Gratzke, Christian, additional, Kramer, Mario W., additional, Katalinic, Alexander, additional, and Merseburger, Axel S., additional
- Published
- 2021
- Full Text
- View/download PDF
12. Investigating the mechanism of the Hsp90 molecular chaperone using photoinduced electron transfer fluorescence quenching
- Author
-
Schulze, Andrea
- Subjects
570 Biowissenschaften ,Biologie - Published
- 2020
- Full Text
- View/download PDF
13. Formation and emission of chloroanisoles as indoor pollutants
- Author
-
Gunschera, Jan, Fuhrmann, Frank, Salthammer, Tunga, Schulze, Andrea, and Uhde, Erik
- Published
- 2004
- Full Text
- View/download PDF
14. Insertion experience of women and health care professionals in the Kyleena® Satisfaction Study
- Author
-
Beckert, Vita, primary, Aqua, Keith, additional, Bechtel, Christoph, additional, Cornago, Sonia, additional, Kallner, Helena Kopp, additional, Schulze, Andrea, additional, Parashar, Pooja, additional, Waddington, Ashley, additional, and Donders, Gilbert, additional
- Published
- 2020
- Full Text
- View/download PDF
15. Perioperative complications following sagittal split osteotomy of the mandible
- Author
-
Teltzrow, Thomas, Kramer, Franz-Josef, Schulze, Andrea, Baethge, Carola, and Brachvogel, Peter
- Published
- 2005
- Full Text
- View/download PDF
16. Insertion experience of women and health care professionals in the Kyleena® Satisfaction Study.
- Author
-
Beckert, Vita, Aqua, Keith, Bechtel, Christoph, Cornago, Sonia, Kallner, Helena Kopp, Schulze, Andrea, Parashar, Pooja, Waddington, Ashley, and Donders, Gilbert
- Abstract
Purpose: The Kyleena® Satisfaction Study (KYSS) is a prospective, observational study conducted to assess satisfaction with LNG-IUS 12 (Kyleena®) in clinical practice and aims to provide adequate information for counselling women on what to expect regarding insertion and satisfaction.Materials and methods: Women deciding to use LNG-IUS 12 during routine counselling were informed of the study and provided informed consent. A baseline analysis was conducted to evaluate demographics, ease of insertion assessed by investigators, pain at insertion rated by women, additional interventions for insertion, and adverse events.Results: 1,110 women (536 parous, 574 nulliparous) had an insertion attempt and were included. Insertion was rated as easy in 494 (92.2%) parous and 516 (89.9%) nulliparous women. Pain was assessed as none or mild by 475 (88.6%) parous and 387 (67.4%) nulliparous women. Additional interventions were not required for most insertions (705; 63.6%). Overall 111 (10.0%) women reported adverse events at the time of baseline analysis.Conclusions: This analysis demonstrates that LNG-IUS 12 insertion is easy and associated with no or mild pain in most women. Additional interventions for insertion are not required in most cases. After 3 months, the number of adverse events is low.Implications: The present baseline analysis of the Kyleena® Satisfaction Study (KYSS) demonstrates that most women rate insertion pain of LNG-IUS 12 as none or mild and clinicians consider insertion easy in the majority of cases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Plasmid DNA Profiles of Acinetobacter Baumannii: Clinical Application in a Complex Endemic Setting
- Author
-
Seifert, Harald, Boullion, Bertil, Schulze, Andrea, and Pulverer, Gerhard
- Published
- 1994
18. Long-term safety of interferon beta-1b (IFNB-1b) treatment in early multiple sclerosis ( MS): The 11-year follow-up of BENEFIT (BENEFIT-11)
- Author
-
Freedman, Mark S., Kappos, Ludwig, Edan, Gilles, Montalban, Xavier, Hartung, Hans-Peter, Hemmer, Bernhard, Fox, Edward, Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo A., Wicklein, Eva-Maria, Department of Biomedicine [Basel], University Hospital Basel [Basel], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Vall d'Hebron University Hospital [Barcelona], Department of neurology, Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), Central Texas Neurology Consultants [Round Rock], VU University Medical Center [Amsterdam], University hospital of Zurich [Zurich], PAREXEL International [Berlin], Myelo Therapeutics [Berlin], Bayer Pharma AG [Berlin], Rheinische Friedrich-Wilhelms-Universität Bonn, Jonchère, Laurent, and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract: P028 - ACTRIMS Forum, New Orleans, LA, feb 2016
- Published
- 2016
19. Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11) (P7.012)
- Author
-
Edan, Gilles, Freedman, Mark, Montalban, Xavier, Miller, David, Hartung, Hans, Hemmer, Bernhard, Fox, Edward, Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo, Wicklein, Eva-Maria, Kappos, Ludwig, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Ottawa Hospital Research Institute [Ottawa] (OHRI), Vall d'Hebron University Hospital [Barcelona], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), Central Texas Neurology Consultants [Round Rock], VU University Medical Center [Amsterdam], University hospital of Zurich [Zurich], PAREXEL International [Berlin], Myelo Therapeutics [Berlin], Bayer Pharma AG [Berlin], Rheinische Friedrich-Wilhelms-Universität Bonn, Bayer HealthCare Pharmaceuticals Inc [Whippany], Department of Biomedicine [Basel], University Hospital Basel [Basel], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] - Abstract
International audience; OBJECTIVE:To study long-term outcomes in patients treated with IFNB-1b after clinically isolated syndrome (CIS). BACKGROUND:In BENEFIT, patients with CIS were randomized to IFNB-1b or placebo (PL) treatment. After the second clinical event or after 2 years, all patients were treated with IFNB-1b. Mean delay of IFNB-1b in PL was 1.33 years. Comprehensive clinical, MRI, and PROs at 11 years post-randomization are reported. DESIGN/METHODS:All originally randomized patients were asked to undergo clinical, MRI, laboratory, and PRO assessments 11 years after randomization. RESULTS:281 patients were identified (60[percnt] of originally randomized, 72.6[percnt] of eligible patients at participating sites); 278 enrolled. Baseline characteristics were similar to the original BENEFIT population. At Year 11, patients randomized to IFNB-1b still had lower overall annualized relapse rate (p=0.0018) and longer time to first relapse (p=0.0005) and clinically definite MS (p=0.0012). Median EDSS score was 2.0 (change from baseline 0.5) in both groups. PASAT scores remained high (overall median 56 [IQR 10]). Of the 81.3[percnt] working at CIS start, 73.4[percnt] were still employed (64.4[percnt] fulltime). 12.2[percnt] retired early or were on long-term disability (2.9[percnt] at baseline). 64.0[percnt] did not report any sick leave during the past 12 months. Health-related quality of life remained stable (median [IQR] change from baseline EQ-5D: 0.000 [0.209], FAMS TOI: -7.54 [27.17]. Median (IQR) fatigue (FSMC) score: 45.00 (40.00), 46[percnt] of patients without fatigue (cut-off score\textless43), median (IQR) depression (CES-D) score: 9.00 (15.00). MRI findings were similar across groups: 86.4[percnt] had no gadolinium-enhancing lesions; median (IQR) number of new T2 lesions since 5-year MRI: 2.0 (6.0), T2 volume: 1760.0mm³ (3963.0mm³), cortical lesions: 2.0 (5.0), brain volume 1519.0cm³ (152.0mm³), mean cortical thickness 2.64mm³ (0.56mm³). CONCLUSIONS:Results from BENEFIT11 support a long-term impact of early treatment with IFNB-1b on clinical measures, including cognition and fatigue, and health economic and MRI outcomes. Study Supported by:Bayer HealthCare Pharmaceuticals Disclosure: Dr. Edan has received personal compensation for activities with LFB, Biogenidec, speaking from Serono, Inc., Sanofi, Teva, and Bayer Pharmaceuticals Corporation as a consultant and/or scientific advisory board member. Dr. Freedman has received personal compensation for activities with Bayer Healthcare, Biogen Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis, and Teva Canada Innovation. Dr. Montalban has received personal compensation for activities with Bayer, Biogen Idec, EMD, Genentech, Genzyme, Merck Serono, Neurotec, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, and Almirall. Dr. Miller has received personal compensation for activities with UCL Institute of Neurology, Biogen Idec, GlaxoSmithKline Inc., Novartis, Merck & Co. Inc., Chugai, and Mitsubishi Pharma. Dr. Miller has received personal compensation in an editorial capac Dr. Hartung has holds stock and/or stock options from Opexa Therapeutics. Dr. Hemmer has received personal compensation for activities with Roche, Novartis, Bayer Schering, Merck Serono, Biogen Idec, GlaxoSmithKline, Chugai Pharmaceutical, Micromet, and Genzyme as a scientific advisory board member. Dr. Fox has received personal compensation for activities Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Eli Lilly & Company, EMD Serono, Genzyme Corporation, GlaxoSmithKline, and Novartis. Dr. Barkhof has received personal compensation for activities with Bayer Schering Pharma, Sanofi, Genzyme, Biogen Idec, Teva, Merck Serono, Novartis, Roche, Synthon BV, and Janssen Research as a consultant. Dr. Schippling has received personal compensation for activities with Novartis. Dr. Schippling has received research support from Bayer Schering and Biogen Idec. Dr. Schulze has received personal compensation for activities with PAREXEL International as an employee. Dr. Pleimes has received personal compensation for activities with Myelo Therapeutics GmbH as an employee, and with Bayer Pharmaceuticals Corp. as an employee and consultant. Dr. Pohl has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Pohl owns stock and/or stock options in Bayer Pharmaceuticals Corporation. Dr. Sandbrink has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Sandbrink holds stock and/or stock options in Bayer Pharmaceuticals Corporation. Dr. Suarez has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Wicklein has received personal compensation for activities with Bayer Pharmaceuticals Corporation as an employee. Dr. Kappos has received personal compensation for activities with Actelion Pharmaceuticals
- Published
- 2015
20. Überlappungen zerebraler Verarbeitungsprozesse von Schmerz und negativen Emotionen: eine Metaanalyse aus 138 fMRT-Studien
- Author
-
Schulze, Andrea, Henningsen, Peter (Prof. Dr.), and Gündel, Harald (Prof. Dr.)
- Subjects
Medizin und Gesundheit ,Schmerz, Emotion, fMRT, Metaanalyse, Gehirnaktivität ,ddc:610 - Abstract
Auf neuronaler Ebene besteht zwischen der Wahrnehmung von Schmerzen und dem Empfinden negativer Emotionen eine enge Verbindung. Mit Hilfe einer Metaanalyse sollten Überlappungen in diesen Verarbeitungsnetzwerken dargestellt werden. 138 fMRT-Studien bis einschließlich Februar 2007 wurden analysiert. Es handelte sich dabei um 84 Emotionsstudien und 54 Schmerzstudien, deren Ergebnisse in Hinblick auf ihre Koordinatenangaben in 25 Gehirnregionen miteinander verglichen wurden. Die durchgeführte statistische Auswertung zeigte Ähnlichkeiten innerhalb dieser neuronalen Verarbeitungsprozesse hauptsächlich innerhalb von Strukturen des limbischen Systems. The sensation of physical pain and negative emotions is closely connected on a neuronal basis. A meta-analysis was conducted to find overlapping brain activation in the processing of these two perceptions. 138 fMRT-studies until February 2007 have been analysed for this purpose. 84 were studies dealing with negative emotions and 54 studies with pain. The results from these studies were compared using coordinates in 25 different regions of the human brain. The statistical analyses revealed an overlapping of neuronal activity mainly in limbic structures.
- Published
- 2010
21. AG 3: Transfer Vom Wissen zur Wirkung
- Author
-
Haertel, Tobias, Merkator, Nadine, Schulze, Andrea, Tadsen, Wögen, and Valk-Draad, Maria
- Abstract
Journal Hochschuldidaktik ; 21. Jahrgang 2010 Heft 1
- Published
- 2010
22. Journal Hochschuldidaktik Jahrgang 21 (2010) Heft 1
- Author
-
Wildt, Johannes, Jahnke, Isa, Kehm, Barbara M., Bauschke-Urban, Carola, Huchthausen, Maria, Schneider, Ralf, Treeck, Timo Van, Schürmann, Ramona, König, Elena, Scholkmann, Antonia, Haertel, Tobias, Merkator, Nadine, Schulze, Andrea, Valk-Draad, Maria, Wolff-Bendik, Karola, Heiner, Matthias, and Battaglia, Santina
- Abstract
Journal Hochschuldidaktik ; 21. Jahrgang 2010 Heft 1
- Published
- 2010
- Full Text
- View/download PDF
23. A role for the ubiquitin domain protein HERP in ER-associated protein degradation
- Author
-
Schulze, Andrea, Kloetzel, Peter-Michael, Hartmann-Petersen, Rasmus, and Dubiel, Wolfgang
- Subjects
Ubiquitin Domänen Protein ,HERPUD1 ,WE 2401 ,32 Biologie ,macromolecular substances ,UPR ,Proteindegradation ,Ubiquitin-ähnliche Domäne ,HERUD1 ,Ubiquitylierung/Ubiquitinierung ,ddc:570 ,ubiquitin ,ubiquitin-like domain ,570 Biowissenschaften, Biologie ,Endoplasmatisches Retikulum ,UBL-Domäne ,ubiquitylation/ubiquitination ,retrotranslocation ,VIMP ,ERAD ,ubiquitin domain protein ,Derlin-1 ,endoplasmic reticulum ,complex ,proteasome ,HRD1 ,HERP ,Retrotranslokation ,USP7 ,protein degradation ,Proteinkomplex ,UBL domain ,WN 4000 ,Proteasom ,protein ,p97/VCP/Cdc48 - Abstract
Die ER-assoziierte Proteindegradation (ERAD) ist Teil des Qualitätskontrollsystems am ER, um der Akkumulation von fehlgefalteten Proteinen im ER entgegenzuwirken. Hierbei werden ERAD-Substrate mit Hilfe von E3-Ligasen wie z.B. HRD1 ubiquityliert und anschließend durch den p97-Ufd1-Npl4 Komplex aus der ER-Membran extrahiert. Im Zytosol werden diese extrahierten Proteine vom 26S Proteasom abgebaut. Für die Retrotranslokation von ERAD- Substraten werden zudem die Membranproteine Derlin-1 und VIMP benötigt, welche mit p97 assoziieren und einen Proteinkomplex bilden. HERP ist ein ER-lokalisiertes Protein, dessen Synthese durch den UPR (unfolded protein response) als Antwort auf die Akkumulation von fehlgefalteten Proteinen im ER induziert wird. Dies deutet auf eine Rolle von HERP im ERAD hin. Interessanterweise besitzt HERP eine sogenannte UBL-Domäne. Für andere Proteine mit UBL-Domäne konnte eine Interaktion dieser Domäne mit dem Proteasom nachgewiesen werden. Daher kann angenommen werden, dass HERP ebenfalls mit dem Proteasom interagiert und dies zur ER- Membran rekrutiert, wo es für den Abbau von ERAD-Substraten benötigt wird. Das Ziel der vorliegenden Arbeit war es, die Rolle von HERP innerhalb des UPR zu ermitteln. Die hier präsentierten Daten zeigen, dass HERP essentiell für den Abbau des ERAD-Modell- Substrates CD3-delta ist. Somit hat HERP tatsächlich eine Rolle im ERAD. Außerdem wird eine direkte Interaktion von HERP mit der E3-Ligase HRD1 nachgewiesen. Es wird zudem gezeigt, dass HERP und HRD1 einen Proteinkomplex mit p97, Derlin-1 und eventuell auch mit VIMP bilden. Dieser ERAD Komplex ist folglich sowohl für die Ubiquitylierung als auch die Retrotranslokation von ERAD-Substraten verantwortlich und garantiert somit die effiziente Prozessierung von Proteinen aus dem ER. Zudem wird gezeigt, dass die UBL-Domäne von HERP im Gegensatz zu anderen UBL- Domänen nicht mit dem Proteasom interagiert. Somit kann nicht mehr davon ausgegangen werden, dass Proteasombindung eine Gemeinsamkeit aller Proteine mit UBL-Domäne ist. Dagegen wird eine Interaktion der UBL-Domäne von HERP mit dem deubiquitylierenden Enzym USP7 nachgewiesen. Dies deutet darauf hin, dass auch Deubiquitylierung eine wichtige Rolle im ERAD-Prozess spielt. ER-associated protein degradation (ERAD) is part of the ER quality control system dealing with the accumulation of misfolded proteins in the ER. This process requires polyubiquitylation of ERAD substrates involving E3 ligases, such as HRD1, and their subsequent extraction from the ER membrane by the p97-Ufd1-Npl4 complex. Retrotranslocation of substrates into the cytosol for degradation by the 26S proteasome also involves the membrane proteins Derlin-1 and VIMP, which are associated with p97 to form a protein complex. The ER-resident protein HERP was shown to be upregulated by the unfolded protein response pathway (UPR) upon the accumulation of misfolded proteins in the ER. It was therefore considered to function in ERAD. Interestingly, HERP contains a UBL domain. In other proteins this domain facilitates an interaction with the proteasome, suggesting that HERP might recruit the proteasome to the ER membrane for efficient ERAD. The aim of this study was to investigate the function of HERP within the UPR. The findings presented here demonstrate that HERP is essential for the degradation of a model ERAD substrate. Thus, HERP indeed has a role in ERAD. Moreover, the data show that HERP directly interacts with the E3 ligase HRD1 and the two proteins form a common protein complex with p97, Derlin-1 and possibly also with VIMP. This suggests that both ubiquitylation and retrotranslocation of ER proteins are performed by one protein complex, enabling an efficient processing of ERAD substrates. This study also demonstrates that the UBL domain of HERP does not share the proteasome binding property of other UBL domains, suggesting that proteasome binding cannot be considered a general feature of all UBL domains. Instead, the HERP UBL domain is able to interact with the deubiquitylating enzyme USP7. Therefore, deubiquitylation might also be an important aspect in the proteasome-dependent degradation of misfolded ER proteins.
- Published
- 2007
24. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
- Author
-
Kappos, Ludwig, Edan, Gilles, Freedman, Mark S., Montalbán, Xavier, Hartung, Hans-Peter, Hemmer, Bernhard, Fox, Edward J., Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo, and Wicklein, Eva-Maria
- Published
- 2016
- Full Text
- View/download PDF
25. Ubiquitin domain proteins in disease
- Author
-
Madsen, Louise, primary, Schulze, Andrea, additional, Seeger, Michael, additional, and Hartmann-Petersen, Rasmus, additional
- Published
- 2007
- Full Text
- View/download PDF
26. Nasalance in patients with maxillary defects – Reconstruction versus obturation
- Author
-
Eckardt, André, primary, Teltzrow, Thomas, additional, Schulze, Andrea, additional, Hoppe, Marijana, additional, and Kuettner, Christian, additional
- Published
- 2007
- Full Text
- View/download PDF
27. The Ubiquitin-domain Protein HERP forms a Complex with Components of the Endoplasmic Reticulum Associated Degradation Pathway
- Author
-
Schulze, Andrea, primary, Standera, Sybille, additional, Buerger, Elke, additional, Kikkert, Marjolein, additional, van Voorden, Sjaak, additional, Wiertz, Emmanuel, additional, Koning, Frits, additional, Kloetzel, Peter-Michael, additional, and Seeger, Michael, additional
- Published
- 2005
- Full Text
- View/download PDF
28. Rezensionen
- Author
-
Schulze, Andrea, primary
- Published
- 2004
- Full Text
- View/download PDF
29. Intra- and Perioperative Complications of the LeFort I Osteotomy: A Prospective Evaluation of 1000 Patients
- Author
-
Kramer, Franz-Josef, primary, Baethge, Carola, additional, Swennen, Gwen, additional, Teltzrow, Thomas, additional, Schulze, Andrea, additional, Berten, Johannes, additional, and Brachvogel, Peter, additional
- Published
- 2004
- Full Text
- View/download PDF
30. Coronin 7, the mammalian POD‐1 homologue, localizes to the Golgi apparatus
- Author
-
Rybakin, Vasily, primary, Stumpf, Maria, additional, Schulze, Andrea, additional, Majoul, Irina V., additional, Noegel, Angelika A., additional, and Hasse, Andreas, additional
- Published
- 2004
- Full Text
- View/download PDF
31. The Distribution of Acinetobacter Species in Clinical Culture Materials
- Author
-
Seifert, Harald, primary, Baginski, Rainer, additional, Schulze, Andrea, additional, and Pulverer, Gerhard, additional
- Published
- 1993
- Full Text
- View/download PDF
32. Vom praktischen Sinn ökumenischer Forschung. Koreferat zum Vortrag von Dietrich Ritschl
- Author
-
Schäfer, Heinrich, Schulze, Andrea, von Sinner, Rudolf, and Stierle, Wolfram
33. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
- Author
-
Kappos, Ludwig, Edan, Gilles, Freedman, Mark S., Montalbán, Xavier, Hartung, Hans-Peter, Hemmer, Bernhard, Fox, Edward J., Barkhof, Frederik, Schippling, Sven, Schulze, Andrea, Pleimes, Dirk, Pohl, Christoph, Sandbrink, Rupert, Suarez, Gustavo, Wicklein, Eva-Maria, Csiba, László, Csépány, Tünde, University of Basel (Unibas), Vision, Action et Gestion d'informations en Santé (VisAGeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Ottawa Hospital Research Institute [Ottawa] (OHRI), Vall d'Hebron University Hospital [Barcelona], Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Munich Cluster for systems neurology [Munich] (SyNergy), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM)-Ludwig-Maximilians-Universität München (LMU), Virginia Tech [Blacksburg], University hospital of Zurich [Zurich], PAREXEL International [Berlin], VU University Medical Center [Amsterdam], Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Bayer HealthCare Pharmaceuticals Inc [Whippany], Bayer Pharma AG [Berlin], University of Zurich, Kappos, L, Edan, Gilles, CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Dubois, Bénédicte, Department of Neurology [Suisse], University Hospital Basel [Basel], Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec, Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], The Ottawa Hospital, Medical Image Analysis Center (MIAC AG), Department of neurology, Heinrich-Heine-Universität Düsseldorf [Düsseldorf], Munich Cluster of Systems Neurology (SyNery), Department Neurology of the Klinikum rechts der Isar, Technische Universität München [München] (TUM), Myelo Therapeutics [Berlin], Consejo Nacional de Investigaciones Científicas y Técnicas [Buenos Aires] (CONICET), Klinische Neurowetenschappen, MUMC+: MA Med Staf Spec Neurologie (9), RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Technische Universität München [München] (TUM)-Ludwig-Maximilians-Universität München (LMU), Radiology and nuclear medicine, and Amsterdam Neuroscience - Neuroinfection & -inflammation
- Subjects
0301 basic medicine ,Male ,Cross-sectional study ,MESH: Adjuvants, Immunologic ,Kaplan-Meier Estimate ,Disability Evaluation ,0302 clinical medicine ,Recurrence ,Medicine ,MESH: Double-Blind Method ,Young adult ,10. No inequality ,MESH: Treatment Outcome ,Clinically isolated syndrome ,MESH: Disability Evaluation ,Orvostudományok ,MESH: Follow-Up Studies ,3. Good health ,Treatment Outcome ,2728 Neurology (clinical) ,MESH: Young Adult ,Female ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Interferon beta-1b ,Adult ,medicine.medical_specialty ,Randomization ,MESH: Demyelinating Diseases ,610 Medicine & health ,MESH: Interferon beta-1b ,Placebo ,Klinikai orvostudományok ,Article ,Time-to-Treatment ,03 medical and health sciences ,Young Adult ,MESH: Cross-Sectional Studies ,Adjuvants, Immunologic ,Double-Blind Method ,Immunologic/administration & dosage* Adult Cross-Sectional Studies Demyelinating Diseases/diagnostic imaging Demyelinating Diseases/drug therapy* Disability Evaluation Double-Blind Method Female Follow-Up Studies Humans Interferon beta-1b/administration & dosage* Kaplan-Meier Estimate Male Recurrence Time-to-Treatment Treatment Outcome Young Adult ,Internal medicine ,Humans ,Adjuvants ,[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,MESH: Time-to-Treatment ,MESH: Kaplan-Meier Estimate ,Expanded Disability Status Scale ,MESH: Humans ,business.industry ,Multiple sclerosis ,MESH: Adult ,medicine.disease ,MESH: Male ,Surgery ,10040 Clinic for Neurology ,MESH: Recurrence ,030104 developmental biology ,Cross-Sectional Studies ,Neurology (clinical) ,business ,MESH: Female ,030217 neurology & neurosurgery ,Demyelinating Diseases ,Follow-Up Studies - Abstract
Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinicallyisolated syndrome (CIS) or after a short delay.Methods: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment)were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayedtreatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients onplacebo could switch to interferon beta-1b or another treatment. Eleven years after randomization,patients were reassessed.Results: Two hundred seventy-eight (59.4%) of the original 468 patients (71.3% of those eligible atparticipating sites) were enrolled (early: 167 [57.2%]; delayed: 111 [63.1%]). After 11 years, risk ofCDMS remained lower in the early-treatment arm compared with the delayed-treatment arm (p 50.0012), with longer time to first relapse (median [Q1, Q3] days: 1,888 [540, not reached] vs 931[253, 3,296]; p50.0005) and lower overall annualized relapse rate (0.21 vs 0.26; p50.0018). Only25 patients (5.9%, overall; early, 4.5%; delayed, 8.3%) converted to secondary progressive multiplesclerosis. Expanded Disability Status Scale scores remained low and stable, with no differencebetween treatment arms (median [Q1,Q3]: 2.0 [1.0, 3.0]). The early-treatment group had better PacedAuditory Serial Addition Task–3 total scores (p 5 0.0070). Employment rates remained high, andhealth resource utilization tended to be low in both groups.MRI metrics did not differ between groups.Conclusions: Although the delay in treatment was relatively short, several clinical outcomesfavored earlier treatment. Along with low rates of disability and disease progression in bothgroups, this supports the value of treatment at CIS., NCT01795872.
34. Insertion experience of women and health care professionals in the Kyleena ® Satisfaction Study.
- Author
-
Beckert V, Aqua K, Bechtel C, Cornago S, Kallner HK, Schulze A, Parashar P, Waddington A, and Donders G
- Subjects
- Adolescent, Adult, Female, Humans, Prospective Studies, Young Adult, Contraceptive Agents, Female administration & dosage, Intrauterine Devices, Medicated, Levonorgestrel administration & dosage, Pain, Procedural etiology, Patient Satisfaction statistics & numerical data
- Abstract
Purpose: The Kyleena
® Satisfaction Study (KYSS) is a prospective, observational study conducted to assess satisfaction with LNG-IUS 12 (Kyleena® ) in clinical practice and aims to provide adequate information for counselling women on what to expect regarding insertion and satisfaction. Materials and methods: Women deciding to use LNG-IUS 12 during routine counselling were informed of the study and provided informed consent. A baseline analysis was conducted to evaluate demographics, ease of insertion assessed by investigators, pain at insertion rated by women, additional interventions for insertion, and adverse events. Results: 1,110 women (536 parous, 574 nulliparous) had an insertion attempt and were included. Insertion was rated as easy in 494 (92.2%) parous and 516 (89.9%) nulliparous women. Pain was assessed as none or mild by 475 (88.6%) parous and 387 (67.4%) nulliparous women. Additional interventions were not required for most insertions (705; 63.6%). Overall 111 (10.0%) women reported adverse events at the time of baseline analysis. Conclusions: This analysis demonstrates that LNG-IUS 12 insertion is easy and associated with no or mild pain in most women. Additional interventions for insertion are not required in most cases. After 3 months, the number of adverse events is low. Implications: The present baseline analysis of the Kyleena® Satisfaction Study (KYSS) demonstrates that most women rate insertion pain of LNG-IUS 12 as none or mild and clinicians consider insertion easy in the majority of cases.- Published
- 2020
- Full Text
- View/download PDF
35. Complete nucleotide sequence and evolutionary analysis of a gorilla foamy virus.
- Author
-
Schulze A, Lemey P, Schubert J, McClure MO, Rethwilm A, and Bodem J
- Subjects
- Amino Acid Motifs, Animals, Cloning, Molecular, Cluster Analysis, Conserved Sequence, Gene Products, env genetics, Gene Products, gag genetics, Gene Products, pol genetics, Genetic Vectors, Molecular Sequence Data, Phylogeny, Plasmids, RNA, Viral genetics, Sequence Analysis, DNA, Sequence Homology, Simian foamy virus isolation & purification, Base Sequence, Genome, Viral, Gorilla gorilla virology, Simian foamy virus genetics
- Abstract
To shed light on primate foamy virus (FV) evolution, we determined the complete nucleotide sequence of the gorilla simian foamy virus (SFVgor). Starting from a conserved region in the integrase (IN) domain of the pol gene we cloned the viral genome to the 5' and 3' LTR into plasmid vectors and elucidated its nucleotide sequence. The sequences of both LTRs were determined by nucleotide sequencing of separate PCR products from the primer-binding site or the bel region and LTRs. All protein motifs conserved among the primate FV were identified in SFVgor. Using phylogenetic analysis of the Gag, Pol and Env amino acid sequences, we demonstrate that SFVgor consistently clusters in accordance with a scenario of virus-host co-divergence.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.